Treatment options for chronic myeloid leukemia

Author： Tanaka Maria Florencia   Kantarjian Hagop   Cortes Jorge   Ohanian Maro   Jabbour Elias  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.6, 2012-04, pp. : 815-828

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of chronic myeloid leukemia when imatinib fails

By Hehlmann Rüdiger   Jung-Munkwitz Susanne   Saußele Susanne  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 269-283

Informa Healthcare

Access to resources Recommend Favorite

Mathematical Modeling of Genesis and Treatment of Chronic Myeloid Leukemia

By  

Cells Tissues Organs, Vol. 188, Iss. 1-2, 2008-02 ,pp. : 236-247

Karger

Access to resources Recommend Favorite

Interferon alpha for Treatment of Chronic Myeloid Leukemia

By  

Current Drug Targets, Vol. 12, Iss. 3, 2011-03 ,pp. : 420-428

Bentham Science Publishers

Access to resources Recommend Favorite

New treatment options for chronic lymphocytic leukemia

By Delgado Julio   Baumann Tycho   Santacruz Rodrigo   Montserrat Emili  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 823-832

Informa Healthcare

Access to resources Recommend Favorite

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia

By Fullmer Amber   Kantarjian Hagop   Cortes Jorge   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3065-3072

Informa Healthcare

Access to resources Recommend Favorite